Increase in brain-derived neurotrophic factor in patients with schizophrenia treated with olanzapine: A systemic review and meta-analysis

Journal of Experimental and Clinical Medicine

Volumn 4, Issue 2, 2012, Pages 119-124

  Lin, Pao Yen ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Brain derived neurotrophic factor (BDNF); Meta analysis; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; CITATION ANALYSIS; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

EID: 84859573226     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2012.02.002     Document Type: Article

References (41)

1. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005, 10:434-449.
2. Dechant G., Neumann H. Neurotrophins. Adv Exp Med Biol 2002, 513:303-334.
3. Weickert C.S., Hyde T.M., Lipska B.K., Herman M.M., Weinberger D.R., Kleinman J.E. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2003, 8:592-610.
4. Weickert C.S., Ligons D.L., Romanczyk T., Ungaro G., Hyde T.M., Herman M.M., Weinberger D.R., et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005, 10:637-650.
5. Thompson Ray M., Weickert C.S., Wyatt E., Webster M.J. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011, 36:195-203.
6. Favalli G., Li J., Belmonte-de-Abreu P., Wong A.H., Daskalakis Z.J. The role of BDNF in the pathophysiology and treatment of schizophrenia. J Psychiatr Res 2012, 46:1-11.
7. Green M.J., Matheson S.L., Shepherd A., Weickert C.S., Carr V.J. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 2011, 16:960-972.
8. Rizos E.N., Papadopoulou A., Laskos E., Michalopoulou P.G., Kastania A., Vasilopoulos D., Katsafouros K., et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry 2010, 11:251-255.
9. Chen C.C., Huang T.L. Effects of antipsychotics on the serum BDNF levels in schizophrenia. Psychiatry Res 2011, 189:327-330.
10. Pirildar S., Gonul A.S., Taneli F., Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:709-713.
11. Hori H., Yoshimura R., Yamada Y., Ikenouchi A., Mitoma M., Ida Y., Nakamura J. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. Int Clin Psychopharmacol 2007, 22:21-27.
12. Yoshimura R., Hori H., Sugita A., Ueda N., Kakihara S., Umene W., Nakano Y., et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1072-1077.
13. Shadish W.R., Haddock C.K. Combining estimates of effect size. The handbook of research synthesis 1994, 261-281. Russell Sage Foundation, New York. H. Cooper, L.V. Hedges (Eds.).
14. Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. Introduction to meta-analysis 2009, John Wiley & Sons, Chichester.
15. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
16. Peters J.L., Sutton A.J., Jones D.R., Abrams K.R., Rushton L. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 2007, 26:4544-4562.
17. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gotzsche P.C., Ioannidis J.P., Clarke M., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
18. Palomino A., Vallejo-Illarramendi A., Gonzalez-Pinto A., Aldama A., Gonzalez-Gomez C., Mosquera F., Gonzalez-Garcia G., et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006, 86:321-322.
19. Lee B.H., Kim Y.K. Increased plasma brain-derived neurotropic factor, not nerve growth factor-beta, in schizophrenia patients with better response to risperidone treatment. Neuropsychobiology 2009, 59:51-58.
20. Gonzalez-Pinto A., Mosquera F., Palomino A., Alberich S., Gutierrez A., Haidar K., Vega P., et al. Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics. Int Clin Psychopharmacol 2010, 25:241-245.
21. Yoshimura R., Ueda N., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2010, 11:256-261.
22. Lee A.H., Lange C., Ricken R., Hellweg R., Lang U.E. Reduced brain-derived neurotrophic factor serum concentrations in acute schizophrenic patients increase during antipsychotic treatment. J Clin Psychopharmacol 2011, 31:334-336.
23. Ukai W., Ozawa H., Tateno M., Hashimoto E., Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J Neural Transm 2004, 111:667-681.
24. Bai O., Chlan-Fourney J., Bowen R., Keegan D., Li X.M. Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. J Neurosci Res 2003, 71:127-131.
25. Park S.W., Lee C.H., Lee J.G., Lee S.J., Kim N.R., Choi S.M., Kim Y.H. Differential effects of ziprasidone and haloperidol on immobilization stress-induced mRNA BDNF expression in the hippocampus and neocortex of rats. J Psychiatr Res 2009, 43:274-281.
26. Park S.W., Lee J.G., Ha E.K., Choi S.M., Cho H.Y., Seo M.K., Kim Y.H. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Y cells. Eur Neuropsychopharmacol 2009, 19:356-362.
27. Pillai A., Terry A.V., Mahadik S.P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res 2006, 82:95-106.
28. Park S.W., Phuong V.T., Lee C.H., Lee J.G., Seo M.K., Cho H.Y., Fang Z.H., et al. Effects of antipsychotic drugs on BDNF, GSK-3beta, and beta-catenin expression in rats subjected to immobilization stress. Neurosci Res 2011, 71:335-340.
29. Lu X.H., Bradley R.J., Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res 2004, 1011:58-68.
30. Heiser P., Enning F., Krieg J.C., Vedder H. Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro. J Psychopharmacol (Oxf) 2007, 21:851-856.
31. Hammonds M.D., Shim S.S. Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 2009, 105:113-119.
32. Czubak A., Nowakowska E., Kus K., Burda K., Metelska J., Baer-Dubowska W., Cichocki M. Influences of chronic venlafaxine, olanzapine and nicotine on the hippocampal and cortical concentrations of brain-derived neurotrophic factor (BDNF). Pharmacol Rep 2009, 61:1017-1023.
33. Lee J.G., Cho H.Y., Park S.W., Seo M.K., Kim Y.H. Effects of olanzapine on brain-derived neurotrophic factor gene promoter activity in SH-SY5Y neuroblastoma cells. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1001-1006.
34. Angelucci F., Aloe L., Iannitelli A., Gruber S.H., Mathe A.A. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 2005, 15:311-317.
35. Becker A., Grecksch G., Schwegler H., Roskoden T. Expression of mRNA of neurotrophic factors and their receptors are significantly altered after subchronic ketamine treatment. Med Chem 2008, 4:256-263.
36. Tan Q.R., Wang X.Z., Wang C.Y., Liu X.J., Chen Y.C., Wang H.H., Zhang R.G., et al. Differential effects of classical and atypical antipsychotic drugs on rotenone-induced neurotoxicity in PC12 cells. Eur Neuropsychopharmacol 2007, 17:768-773.
37. Angelucci F., Mathe A.A., Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J Neurosci Res 2000, 60:783-794.
38. Keilhoff G., Grecksch G., Bernstein H.G., Roskoden T., Becker A. Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psychiatry Clin Neurosci 2010, 260:151-162.
39. Lin P.Y. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett 2009, 466:139-143.
40. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008, 64:527-532.
41. Saito S., Watanabe K., Hashimoto E., Saito T. Low serum BDNF and food intake regulation: a possible new explanation of the pathophysiology of eating disorders. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:312-316.